The Pharma and Biotech Patent Litigation Conference
Monday, January 19, 2026 -- Wednesday, January 21, 2026, 0900 - 1700
The Pharma and Biotech Patent Litigation Track at the Patent Litigation Europe Summit 2026 is the leading European forum for life sciences IP counsel and litigators to benchmark enforcement strategies, navigate evolving UPC case law, and prepare for the next wave of biosimilar and generic challenges. Taking place on 20–21 January 2026 at the Beurs van Berlage in Amsterdam, the track continues the legacy of the Pharma and Biotech Patent Litigation Summit while introducing a broader cross-sector environment under the newly rebranded Patent Litigation Europe umbrella.
This stream remains the anchor event for the life sciences audience, attracting around 600 attendees, with an exceptional 45% in-house counsel ratio from leading pharmaceutical innovators, biotechs, generics and biosimilar developers. The track will again be hosted in the dedicated Pharma and Biotech conference room, while sharing networking spaces and sessions with attendees from the Tech and Innovation Patent Litigation track, enabling delegates to connect across industries and discuss the strategic overlaps between life sciences, AI, and regulatory-driven IP enforcement.
The Pharma and Biotech agenda focuses on the issues that define market exclusivity and drive litigation across Europe. Topics include: preliminary injunctions, UPC procedures and case law, Supplementary Protection Certificates (SPCs), Bolar exemptions, second medical use claims, and biosimilar launch strategies. The programme explores how companies can defend exclusivity, manage parallel litigation across jurisdictions, and adapt to the unified enforcement landscape emerging under the Unified Patent Court (UPC), which now has over 1000 filings and is reshaping European patent practice.
A central theme of the track is the relationship between innovation protection and patient access. Sessions will examine the complex litigation landscape between originators and generics/biosimilars, assessing how recent UPC and national court decisions impact filing strategy, data protection, and lifecycle management. Expert case studies will explore how litigators balance enforcement with commercial realities, providing attendees with practical insights to strengthen internal decision-making and align legal, regulatory, and business objectives.
They are joined by senior IP and legal representatives from companies such as Novo Nordisk, Recordati, Valneva, Orion, Silence Therapeutics, Polpharma, Bruker, Regeneron, and Siemens Healthineers, alongside leading European patent litigators from Powell Gilbert, Kirkland and Ellis, Bardehle Pagenberg, Potter Clarkson, and McCarthy Tetrault. This combination ensures both in-house and private practice perspectives are represented at the highest level.
The track will also include UPC judges, regulatory experts, and litigation funders who will share practical insights on how new procedural and evidentiary frameworks are shaping outcomes across Europe. Delegates will gain clarity on how early UPC judgments are influencing injunction practice, damages calculations, and cross-border enforcement, and how to prepare effective litigation strategies under this new system.
Networking remains at the core of the event. With a structured 1-2-1 meeting programme, shared networking spaces, and curated receptions, attendees can pre-book targeted meetings with key clients, prospects, or peers. This format ensures that law firms, service providers, and corporate legal teams maximise the value of their attendance through meaningful, business-driven interactions.
For life sciences companies, the benefits are clear: the ability to benchmark litigation strategy, learn directly from UPC decision-makers, exchange insights with industry peers, and prepare for future regulatory and market developments that directly impact exclusivity and portfolio value. For private practice litigators, the event provides a concentrated opportunity to reconnect with clients and demonstrate expertise in handling complex, cross-border disputes across Europe's most active jurisdictions.
Above all, the Pharma and Biotech Patent Litigation Track is designed to address the key question at the heart of every life sciences company's patent strategy - how to defend innovation while ensuring commercial success. With its balance of technical, procedural, and strategic content, it provides both depth and practicality, making it the go-to annual meeting for professionals shaping the future of European pharmaceutical patent litigation.
As part of the wider Patent Litigation Europe Summit, this track benefits from the event's broader cross-sector energy, uniting the life sciences community with peers from the technology, automotive, and telecommunications industries. This integrated approach reflects the evolving nature of IP law itself, as AI, data, and platform technologies increasingly intersect with pharma innovation.
URLs:
Website: https://go.evvnt.com/3311939-2?pid=2874
Brochure: https://go.evvnt.com/3311939-3?pid=2874
Brochure: https://go.evvnt.com/3311939-4?pid=2874
Prices:
Tier 1 - In-House Counsel: EUR 499.00,
Tier 2 - Law Firm: EUR 1999.00,
Tier 3 - Service Provider: EUR 2999.00
Category: Conferences | Science, Health and Medicine | Pharmaceuticals
This stream remains the anchor event for the life sciences audience, attracting around 600 attendees, with an exceptional 45% in-house counsel ratio from leading pharmaceutical innovators, biotechs, generics and biosimilar developers. The track will again be hosted in the dedicated Pharma and Biotech conference room, while sharing networking spaces and sessions with attendees from the Tech and Innovation Patent Litigation track, enabling delegates to connect across industries and discuss the strategic overlaps between life sciences, AI, and regulatory-driven IP enforcement.
The Pharma and Biotech agenda focuses on the issues that define market exclusivity and drive litigation across Europe. Topics include: preliminary injunctions, UPC procedures and case law, Supplementary Protection Certificates (SPCs), Bolar exemptions, second medical use claims, and biosimilar launch strategies. The programme explores how companies can defend exclusivity, manage parallel litigation across jurisdictions, and adapt to the unified enforcement landscape emerging under the Unified Patent Court (UPC), which now has over 1000 filings and is reshaping European patent practice.
A central theme of the track is the relationship between innovation protection and patient access. Sessions will examine the complex litigation landscape between originators and generics/biosimilars, assessing how recent UPC and national court decisions impact filing strategy, data protection, and lifecycle management. Expert case studies will explore how litigators balance enforcement with commercial realities, providing attendees with practical insights to strengthen internal decision-making and align legal, regulatory, and business objectives.
They are joined by senior IP and legal representatives from companies such as Novo Nordisk, Recordati, Valneva, Orion, Silence Therapeutics, Polpharma, Bruker, Regeneron, and Siemens Healthineers, alongside leading European patent litigators from Powell Gilbert, Kirkland and Ellis, Bardehle Pagenberg, Potter Clarkson, and McCarthy Tetrault. This combination ensures both in-house and private practice perspectives are represented at the highest level.
The track will also include UPC judges, regulatory experts, and litigation funders who will share practical insights on how new procedural and evidentiary frameworks are shaping outcomes across Europe. Delegates will gain clarity on how early UPC judgments are influencing injunction practice, damages calculations, and cross-border enforcement, and how to prepare effective litigation strategies under this new system.
Networking remains at the core of the event. With a structured 1-2-1 meeting programme, shared networking spaces, and curated receptions, attendees can pre-book targeted meetings with key clients, prospects, or peers. This format ensures that law firms, service providers, and corporate legal teams maximise the value of their attendance through meaningful, business-driven interactions.
For life sciences companies, the benefits are clear: the ability to benchmark litigation strategy, learn directly from UPC decision-makers, exchange insights with industry peers, and prepare for future regulatory and market developments that directly impact exclusivity and portfolio value. For private practice litigators, the event provides a concentrated opportunity to reconnect with clients and demonstrate expertise in handling complex, cross-border disputes across Europe's most active jurisdictions.
Above all, the Pharma and Biotech Patent Litigation Track is designed to address the key question at the heart of every life sciences company's patent strategy - how to defend innovation while ensuring commercial success. With its balance of technical, procedural, and strategic content, it provides both depth and practicality, making it the go-to annual meeting for professionals shaping the future of European pharmaceutical patent litigation.
As part of the wider Patent Litigation Europe Summit, this track benefits from the event's broader cross-sector energy, uniting the life sciences community with peers from the technology, automotive, and telecommunications industries. This integrated approach reflects the evolving nature of IP law itself, as AI, data, and platform technologies increasingly intersect with pharma innovation.
URLs:
Website: https://go.evvnt.com/3311939-2?pid=2874
Brochure: https://go.evvnt.com/3311939-3?pid=2874
Brochure: https://go.evvnt.com/3311939-4?pid=2874
Prices:
Tier 1 - In-House Counsel: EUR 499.00,
Tier 2 - Law Firm: EUR 1999.00,
Tier 3 - Service Provider: EUR 2999.00
Category: Conferences | Science, Health and Medicine | Pharmaceuticals
Starting Price Per Person
€ 499.00 EUR
Other Information
Where
Beurs van Berlage
243 Damrak
Amsterdam 1012 ZJ
Netherlands
( Multi-Purpose Events Venue )
243 Damrak
Amsterdam 1012 ZJ
Netherlands
( Multi-Purpose Events Venue )
Event Organizer Contact
More Events
Event ID: 260027
Get Events in Your Inbox
We have over 100,000 Events in 80+ Categories. Tell us what type of events you like, and we will send them to your inbox